Terran Biosciences CEO to Deliver Keynote Speech at Microdose's 3rd Annual Wonderland Conference
New York, New York--(Newsfile Corp. - November 2, 2023) - Terran Biosciences, a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, today announced that Terran's founder and CEO, Sam Clark, MD, PhD, will be delivering a keynote address at Microdose's 3rd Annual Wonderland Conference in Miami, Florida, November 9th. In his talk entitled "Longevity and the Aging Brain: A Novel Psychedelic-based Therapeutic for Neuroregeneration and Rejuvenation," Dr. Clark will present groundbreaking results from analysis of a clinical imaging study supporting the mechanism of a psychedelic-based therapeutic for neuroregeneration being developed for at-home use.
Terran Biosciences CEO Sam Clark, MD, PhD
To view an enhanced version of this graphic, please visit:
"Our mission is rooted in creating a future that includes treating aging-related diseases through enhanced brain function and rejuvenation," said Dr. Clark. This will be the first presentation of imaging data in humans supporting that the effects of a psychedelic on global brain connectivity and functional neuronal connectivity occur in the absence of a perceptual trip.
In addition to presenting the Keynote, Dr. Clark will lead a workshop, and will be speaking on two panels:
Thursday, November 9th, 3:00 pm EST: Keynote - Longevity and the Aging Brain: A Novel Psychedelic-based Therapeutic for Neuroregeneration and Rejuvenation
Friday, November 10th, 2:00 pm EST: Workshop - Finding the Path at the Intersection of Biopharma, Psychedelics, and Longevity
Friday, November 10th, 10:00 am EST: Patented Psychedelics: The Growing Pharma Field
Friday, November 10th, 12:00 pm EST: Designing the Future: Safer and Effective Psychoactive Compounds for Mental Health
About Terran Biosciences
Terran Biosciences is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases. Terran has built a CNS-focused, tech-enabled drug development platform, and is rapidly advancing a number of late-stage assets, which include novel psychedelic-based therapeutics. With numerous discoveries and more than 200 patent applications in the space, Terran is a leader in developing therapies that bridge the gap between biopharma, psychedelics, and longevity. Follow us on LinkedIn and X.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/186170